Weili Zhao
Ruijin Hospital
Emerging Leaders
not ranked
Current Leaders
#4341 pts
All-Time Leaders
#15,4147 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2012. 14 trials as lead/chair. How it works →
Trials led — by scientific impact
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2RecruitingJuventas Cell Therapy Ltd.
2
impact
Open-label, Dose-escalation Phase 1 Clinical Study of SENL101 Autologous T Cell Injection in the Treatment of Adult Patients With Relapsed or Refractory T-LBL/ALL
Phase 1RecruitingHebei Senlang Biotechnology Inc., Ltd.
2
impact
A Phase 1b/2 Study of a Anti-CD19/CD20 Bispecific CAR-T Therapy (C-CAR039/Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Phase 2RecruitingShanghai AbelZeta Ltd.
1
impact
Prospective, Observational Study on Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Lymphoma Management
N/ARecruitingRuijin Hospital
1
impact
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of iR2 (Ibrutinib，Lenalidomide, Rituximab）in Untreated and Unfit Elderly Patients With Diffuse Large B-cell Lymphoma
Phase 2UnknownRuijin HospitalStudy Chair
0
impact
Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma.
Phase 4UnknownRuijin Hospital
0
impact
0
impact
A Phase II Clinical Trial of S101 Autologous CAR-T Cell Injection for the Treatment of CD7-Positive Relapsed or Refractory T-Lymphoblastic Lymphoma/Leukemia (T-LBL/ALL).
Phase 2Not Yet RecruitingHebei Senlang Biotechnology Inc., Ltd.
0
impact
A Study of Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin (Pirto-R-GemOx±Pola) in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2Not Yet RecruitingRuijin Hospital
0
impact
0
impact
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL: a Single-arm, Multicenter, Open, Phase II Study
Phase 2ActiveShanghai Ming Ju Biotechnology Co., Ltd.
0
impact
(CHANT)A Prospective, Multicenter, Non-interventionistic Real-world Study of Duvelisib Capsules in the Treatment of Non-Hodgkin's Lymphoma (NHL).
N/ANot Yet RecruitingRuijin Hospital
0
impact
A Real-world Study of the Efficacy and Safety of Obinutuzumab-based Therapy for Previously Untreated Follicular Lymphoma
N/ARecruitingRuijin HospitalStudy Chair
0
impact
Selinexor Combined With R-GDP Regimen for TP53-altered Relapsed/Refractory Diffuse Large B-cell Lymphoma: a Single Arm, Single Center, Phase II Study
Phase 2Not Yet RecruitingRuijin HospitalStudy Chair
0
impact
A Umbrella Study in Relapsed/Refractory Peripheral T-cell Lymphoma Guided by Molecular Subtypes
Phase 2UnknownRuijin HospitalStudy Chair
0
impact
A Real World Study of Treatment of Relmacabtagene Autoleucel in Relapsed or Refractory Large B-Cell Lymphoma
N/AUnknownShanghai Ming Ju Biotechnology Co., Ltd.
0
impact
An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Tetra-specific Antibody GNC-038 in Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2ActiveSichuan Baili Pharmaceutical Co., Ltd.
0
impact
An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability，Pharmacokinetic/Pharmacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-035 in Participants With Relapsed/Refractory Hematologic Malignancy and Locally Advanced or Metastatic Solid Tumors
Phase 1ActiveSichuan Baili Pharmaceutical Co., Ltd.
0
impact
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study Evaluating the Efficacy and Safety of Orelabrutinib Plus R-CHOP Versus Placebo Plus R-CHOP in Treatment-naïve Patients With MCD Subtype DLBCL
Phase 3UnknownBeijing InnoCare Pharma Tech Co., Ltd.
0
impact
A Phase II Study on the Safety and Efficacy of Zanubrutinib Combined With Tislelizumab in the Treatment of Relapsed/Refractory Primary Mediastinal Large B-cell Lymphoma and Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
Phase 2UnknownRuijin HospitalStudy Chair
0
impact
CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma, Phase Ⅰ,Open-label,Single-arm,Muticenter Study
Phase 1CompletedShanghai Ming Ju Biotechnology Co., Ltd.
0
impact
The Efficacy and Safety of Azacitidine in Combination With Chidamide in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma Unfit for Conventional Chemotherapy
Phase 2UnknownRuijin HospitalStudy Chair
0
impact
Efficacy and Safety of Cladribine Combined With BEAC ( Semustine, Etoposide, Cytarabine, Cyclophosphamide) Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study
Phase 3UnknownRuijin HospitalStudy Chair
0
impact
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Chidamide Combined With CHOP(Cyclophosphamide, Doxorubicin, Vincristine, Prednisone ) in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma
Phase 2UnknownRuijin HospitalStudy Chair
0
impact
A Metagenome-wide Association Study of Gut Microbiota in Gastrointestinal Non-Hodgkin's Lymphoma Patients
N/AUnknownRuijin HospitalStudy Chair
0
impact
The Efficacy and Safety of Etoposide, Dexamethasone, Peg-asparaginase or Plus Methotrexate With Sandwiched Radiotherapy in the Treatment of Stage I to II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
Phase 3UnknownRuijin Hospital
0
impact